| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2008, p. 1952-1956, Vol. 52, No. 6
0066-4804/08/$08.00+0 doi:10.1128/AAC.01463-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Service de Bactériologie-Virologie, INSERM U914, Emerging Resistance to Antibiotics, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine Paris-Sud, Université Paris XI, 94275 K.-Bicêtre, France,1 Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania,2 University of Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia3
Received 12 November 2007/ Returned for modification 2 February 2008/ Accepted 16 March 2008
A chromosomally encoded class D β-lactamase, OXA-114, was characterized from Achromobacter xylosoxidans strain CIP69598. β-Lactamase OXA-114 shared 56% amino acid identity with the naturally occurring class D β-lactamase of Burkholderia cenocepacia and 42% identity with the acquired oxacillinases OXA-9 and OXA-18. OXA-114 has a narrow-spectrum hydrolysis profile, although it includes imipenem, at a very low level. PCR and sequencing revealed that blaOXA-114-like genes were identified in all A. xylosoxidans strains tested (n = 5), indicating that this β-lactamase is naturally occurring in that species. Induction experiments with imipenem and cefoxitin did not show inducibility of blaOXA-114 expression.
Published ahead of print on 24 March 2008.
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |